| Lilia Lynch, | |
|
133 Biradan Anakko, Dededo, GU 96929-5739 | |
| (671) 645-5500 | |
| Not Available |
| Full Name | Lilia Lynch |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 133 Biradan Anakko, Dededo, Guam |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912475872 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | NP0192 (Guam) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Guam Regional Medical City | Dededo, GU | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guam Healthcare Development Incorporated | 9234351776 | 124 |
| Pacific Med And Nephrology | 1951296490 | 13 |
News Archive
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company's recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Nelson's health insurance covered 90 percent of the costs after a reasonable $500 deductible. I'm happy he has such good health coverage. He's my dog. And I'm jealous of him.
The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
MR Solutions' latest EVO2+ spectrometer now offers the most advanced levels of functionality and user control for constructors of clinical MRI scanners.
› Verified 6 days ago
| Entity Name | Pacific Med & Nephrology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033391313 PECOS PAC ID: 1951296490 Enrollment ID: O20040216000458 |
News Archive
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company's recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Nelson's health insurance covered 90 percent of the costs after a reasonable $500 deductible. I'm happy he has such good health coverage. He's my dog. And I'm jealous of him.
The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
MR Solutions' latest EVO2+ spectrometer now offers the most advanced levels of functionality and user control for constructors of clinical MRI scanners.
› Verified 6 days ago
| Entity Name | Guam Healthcare Development Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326447939 PECOS PAC ID: 9234351776 Enrollment ID: O20150326000266 |
News Archive
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company's recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Nelson's health insurance covered 90 percent of the costs after a reasonable $500 deductible. I'm happy he has such good health coverage. He's my dog. And I'm jealous of him.
The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
MR Solutions' latest EVO2+ spectrometer now offers the most advanced levels of functionality and user control for constructors of clinical MRI scanners.
› Verified 6 days ago
| Entity Name | Guam Dermatology Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306404413 PECOS PAC ID: 7012341456 Enrollment ID: O20191218001233 |
News Archive
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company's recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Nelson's health insurance covered 90 percent of the costs after a reasonable $500 deductible. I'm happy he has such good health coverage. He's my dog. And I'm jealous of him.
The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
MR Solutions' latest EVO2+ spectrometer now offers the most advanced levels of functionality and user control for constructors of clinical MRI scanners.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lilia Lynch, Po Box 290952, Yigo, GU 96929-3045 Ph: (671) 688-2240 | Lilia Lynch, 133 Biradan Anakko, Dededo, GU 96929-5739 Ph: (671) 645-5500 |
News Archive
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company's recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Nelson's health insurance covered 90 percent of the costs after a reasonable $500 deductible. I'm happy he has such good health coverage. He's my dog. And I'm jealous of him.
The percentage of Hispanics in Texas without health insurance has dropped by 30 percent since the Affordable Care Act went into effect, but almost one-third of Hispanic Texans ages 18 to 64 remain uninsured.
Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments, today announced that it has successfully completed a Phase I clinical trial of its lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary brain cancer (glioblastoma or GBM).
MR Solutions' latest EVO2+ spectrometer now offers the most advanced levels of functionality and user control for constructors of clinical MRI scanners.
› Verified 6 days ago
Marianys Delgado Alazo, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5546 | |
Ms. Elizabeth Dizon Santos, AGNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 655 Harmon Loop Rd Ste 300, Dededo, GU 96929 Phone: 671-647-5355 Fax: 671-649-0404 | |
Dr. Bryan Christopher Bansil, DNP, ACNPC-AG Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 133 Route 3, Dededo, GU 96929 Phone: 671-645-5500 | |
Lean Carlo Mendoza Losinio, CNM Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 520 W Santa Monica Ave, Dededo, GU 96929 Phone: 671-635-4422 Fax: 671-635-7493 | |
Ms. Teofila Maria Perez Cruz, MSN, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 520 W Santa Monica Ave, Dededo, GU 96929 Phone: 671-635-7447 | |
Meagan Bamba-ada, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 520 W Santa Monica Ave, Dededo, GU 96929 Phone: 671-687-6235 | |
Maureen L Tang, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 520 W Santa Monica Ave, Dededo, GU 96929 Phone: 671-635-7400 Fax: 671-635-4413 |